Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.59 USD | +1.55% | +3.15% | -10.70% |
Financials (USD)
Sales 2024 * | 1.07M | Sales 2025 * | 200K | Capitalization | 122M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -61M | EV / Sales 2024 * | 7.55 x |
Net cash position 2024 * | 114M | Net cash position 2025 * | 60.6M | EV / Sales 2025 * | 308 x |
P/E ratio 2024 * |
-2.87
x | P/E ratio 2025 * |
-2.34
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.79% |
Latest transcript on Vistagen Therapeutics, Inc.
1 day | +1.55% | ||
1 week | +3.15% | ||
Current month | -4.97% | ||
1 month | -3.37% | ||
3 months | -15.31% | ||
6 months | +39.51% | ||
Current year | -10.70% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 23-08-20 |
Joshua Prince
COO | Chief Operating Officer | 54 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 00-05-31 |
Jerry Gin
BRD | Director/Board Member | 81 | 16-02-29 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 17 M€ | +5.10% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 4.59 | +1.55% | 101,406 |
24-05-14 | 4.52 | -0.22% | 147,669 |
24-05-13 | 4.53 | +3.66% | 69,762 |
24-05-10 | 4.37 | -2.46% | 106,543 |
24-05-09 | 4.48 | +0.67% | 153,524 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.70% | 122M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- VTGN Stock